MX352171B - Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato. - Google Patents

Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.

Info

Publication number
MX352171B
MX352171B MX2014009544A MX2014009544A MX352171B MX 352171 B MX352171 B MX 352171B MX 2014009544 A MX2014009544 A MX 2014009544A MX 2014009544 A MX2014009544 A MX 2014009544A MX 352171 B MX352171 B MX 352171B
Authority
MX
Mexico
Prior art keywords
hemisulfate salt
pyridin
compound
cyclohepta
imidazo
Prior art date
Application number
MX2014009544A
Other languages
English (en)
Other versions
MX2014009544A (es
Inventor
Richard Roberts Daniel
Raymond Schartman Richard
Wei Chenkou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352171(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2014009544A publication Critical patent/MX2014009544A/es
Publication of MX352171B publication Critical patent/MX352171B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe una sal de hemisulfato del Compuesto (I): y formas cristalinas de la sal de hemisulfato. También se describen métodos de uso de la sal de hemisulfato del Compuesto (I) como un antagonista del receptor de CGRP, y composiciones farmacéuticas que comprenden la sal de hemisulfato del Compuesto (I). La sal hemisulfato del Compuesto (I) es útil en tratar, prevenir, o mejorar trastornos que incluyen migraña y otros dolores de cabeza, vasodilatación neurogénica, inflamación neurogénica, lesión térmica, choque circulatorio, sofocos asociados con la menopausia, enfermedades inflamatorias de las vías respiratorias tales como asma, y enfermedad crónica pulmonar obstructiva crónica (EPOC).
MX2014009544A 2012-02-27 2013-02-25 Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato. MX352171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (2)

Publication Number Publication Date
MX2014009544A MX2014009544A (es) 2014-11-10
MX352171B true MX352171B (es) 2017-11-13

Family

ID=47844498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009544A MX352171B (es) 2012-02-27 2013-02-25 Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.

Country Status (25)

Country Link
US (1) US8759372B2 (es)
EP (2) EP3254681B1 (es)
JP (2) JP6208154B2 (es)
KR (2) KR102076118B1 (es)
CN (1) CN104136437B (es)
AU (1) AU2013226361B2 (es)
BR (1) BR112014021032B1 (es)
CA (1) CA2865585C (es)
CY (2) CY1119448T1 (es)
DK (2) DK3254681T3 (es)
EA (1) EA025358B1 (es)
ES (2) ES2642737T3 (es)
HK (1) HK1248111B (es)
HR (2) HRP20171620T1 (es)
HU (2) HUE034936T2 (es)
IL (1) IL234272B (es)
LT (2) LT2820016T (es)
MX (1) MX352171B (es)
NO (1) NO2935439T3 (es)
PL (2) PL2820016T3 (es)
PT (2) PT2820016T (es)
RS (2) RS56556B1 (es)
SG (1) SG11201404834XA (es)
SI (2) SI2820016T1 (es)
WO (1) WO2013130402A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819825T3 (es) 2012-01-26 2021-04-19 Soares Christopher J Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
RS56556B1 (sr) * 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
KR102592899B1 (ko) * 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
BR112020019396A2 (pt) * 2018-03-25 2021-01-05 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant para distúrbios relacionados a cgrt
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
CA3127328A1 (en) * 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164A (zh) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
JPWO2005085228A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 シクロアルカノピリジン誘導体
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
CA2584241A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. Cgrp receptor antagonists
EP2007763A2 (en) 2006-04-10 2008-12-31 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
RS56556B1 (sr) * 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so

Also Published As

Publication number Publication date
CN104136437A (zh) 2014-11-05
IL234272B (en) 2018-10-31
ES2642737T3 (es) 2017-11-17
EP3254681A1 (en) 2017-12-13
JP6476253B2 (ja) 2019-02-27
PT2820016T (pt) 2017-10-18
HRP20171620T1 (hr) 2017-12-01
PT3254681T (pt) 2019-10-01
EP2820016B1 (en) 2017-08-02
SG11201404834XA (en) 2014-09-26
KR102220969B1 (ko) 2021-02-25
HRP20191655T1 (hr) 2019-12-13
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
KR20140130140A (ko) 2014-11-07
RS56556B1 (sr) 2018-02-28
HUE047050T2 (hu) 2020-04-28
DK3254681T3 (da) 2019-09-30
RS59295B1 (sr) 2019-10-31
WO2013130402A1 (en) 2013-09-06
PL3254681T3 (pl) 2019-12-31
KR102076118B1 (ko) 2020-02-11
CY1119448T1 (el) 2018-03-07
EA201491585A1 (ru) 2015-01-30
DK2820016T3 (da) 2017-11-13
EP3254681B1 (en) 2019-06-19
ES2746031T3 (es) 2020-03-04
AU2013226361A1 (en) 2014-10-16
EA025358B1 (ru) 2016-12-30
US8759372B2 (en) 2014-06-24
CN104136437B (zh) 2016-05-11
HUE034936T2 (hu) 2018-03-28
NO2935439T3 (es) 2018-03-31
CY1122121T1 (el) 2020-11-25
US20130225636A1 (en) 2013-08-29
JP6208154B2 (ja) 2017-10-04
LT3254681T (lt) 2019-09-25
CA2865585A1 (en) 2013-09-06
LT2820016T (lt) 2017-10-25
HK1248111B (zh) 2020-04-17
SI2820016T1 (sl) 2017-11-30
AU2013226361B2 (en) 2017-09-21
BR112014021032B1 (pt) 2022-09-27
SI3254681T1 (sl) 2019-10-30
EP2820016A1 (en) 2015-01-07
CA2865585C (en) 2019-12-10
JP2017226693A (ja) 2017-12-28
JP2015511581A (ja) 2015-04-20
KR20200016993A (ko) 2020-02-17
BR112014021032A2 (es) 2017-06-20

Similar Documents

Publication Publication Date Title
MX352171B (es) Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.
TN2012000139A1 (en) Cgrp receptor antagonists
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
TW200628470A (en) Constrained compounds as CGRP-receptor antagonists
WO2005056550A3 (en) Heterocyclic anti-migraine agents
MX2015008481A (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
AR048343A1 (es) Agentes terapeuticos para el tratamiento de la migrana
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
AR080746A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp.
WO2010018109A3 (en) Substituted aminotetralines
TN2015000005A1 (en) Azaindole derivatives which act as pi3k inhibitors
MX2014014711A (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar).
UA95950C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidineasprostaglandin d2 receptor antagonists
MX350862B (es) Acidos de piperidinil naftilacetico.
NZ603800A (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
RU2008118491A (ru) Первичная кислая фосфатная соль антагониста рецептора простагландина d2
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2010018112A3 (en) Monoaryl aminotetralines
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
UA81563C2 (en) Antagonists of calcitonin gene-related peptide receptors
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
TN2017000234A1 (en) Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
ATE517903T1 (de) Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
WO2007131020A3 (en) Constrained compounds as cgrp-receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration